www.Top100Medicine.com - TOP 100 MEDICAL SITES
TOP 100 MEDICAL SITES
 Main  |  Add a Site  |  FREE Content for Your Web-site  |  Bookmark this site  |  Links  |  Webmaster 
Updated Sun, August 22, 2010.
151.www.medizin.de32200
152.www.upmc.com32000
153.www.providence.org31900
154.www.kup.at31400
155.www.dimdi.de31100
156.www.ispesl.it30900
157.www.advocatehealth.com30100
158.www.mskcc.org29600
159.www.mssm.edu29400
160.www.fvdz.de29000
161.www.med.yale.edu28900
162.www.zahnaerzte-nr.de28900
163.www.utsouthwestern.edu28400
164.www.rush.edu27300
165.www.broad.mit.edu27200
166.www.marseille-verlag.com27000
167.www.radiologyinfo.org26400
168.www.chantix.com26100
169.shands.org25900
170.www.bvmed.de25400
171.www.aerzteverlag.de25400
172.doccismef.chu-rouen.fr25300
173.www.cityofhope.org24900
174.www.ospedalecardarelli.it24200
175.www.ispub.com24200
176.www.webapteka.ru23900
177.www.medport.de23600
178.guilde.jeunes-chercheurs.org23600
179.orthopedics.about.com23500
180.www.dkfz-heidelberg.de23500
181.www.bsip.com23400
182.www.cri.it23400
183.www.mamashealth.com23300
184.www.biam2.org23200
185.www.crazymeds.us23000
186.www.dr-gumpert.de22900
187.www.santetropicale.com22900
188.www.ecommunity.com22800
189.www.medynet.com22700
190.www.circulationaha.org22500
191.escuela.med.puc.cl22500
192.www.medizin.uni-halle.de21900
193.www.infodoctor.org21400
194.go-medizin.de21200
195.www.anziani.it20700
196.www.nyp.org20500
197.www.pathguy.com20300
198.www.med.uni-jena.de20100
199.www.mgh.harvard.edu20000
200.www.medicalpicture.de20000
Pages:  1  2  3  4  5  6  7  8  9  10  11  12 
 13  14  15  16 



Subscribe to RSS feed Subscribe to Feed Burner feed Add to Del.icio.us Add to Yahoo Add to Google Add to Reddit Add to Blink Add to Meneame Add to Fark Add to Newsvine

189. www.medynet.com

Rating: 22700 points*
*amount mentions of word 'www.medynet.com' on the other websites

www.medynet.com

El Médico Interactivo, Diario Electrónico de la Sanidad

Description: Diario electrónico de la sanidad, con noticias de actualidad, publicaciones, formación continuada, agenda de congresos y otros servicios.

Most popular searches: medical research, Allergy, www.medynet, wwwmedynet.com, Immunology, health care, www.edynet.com, www.mednet.com, wwwmedynet.com, www.mdynet.com, www.medynetcom, www.meydnet.com, patient, www.medynte.com, www.medyne.com, health, www.medynet.om, physician, www.medynet.ocm, ww.medynet.com, medicine, medical information, drug, www.mdeynet.com, www.medynet.com, www.emdynet.com, Pharmaceutical, www.meynet.com, Cardiac, genome, www.medyent.com, www.medyet.com, ww.medynet.com, vaccines, www.medynt.com, ww.wmedynet.com, doctor, family practice, blood pressure, Nachrichten, www.medynet.co, www.medynetc.om, drug rehab, cholesterol, obesity, asthma, Krankenhaus, www.medynet.cmo, www.mednyet.com, www.medyne.tcom, www.medynet.cm, wwwm.edynet.com,

Google

© 2005-2010 www.Top100Medicine.com
Emory scientist wins $1.5M NSF grant
Emory University chemist Huw Davies got $1.5 million from the National Science Foundation to establish an NSF Center for Chemical Innovation, the Atlanta school said Tuesday.
feeds.bizjournals.com
Setback for Taxus Liberte Stent
Heart stents made by market leader Boston Scientific took a scientific drubbing at a big cardiology conference, after rival products from Medtronic and Abbott Laboratories appeared safer in several studies.
online.wsj.com
Earnings Preview: Amgen
Amgen (AMGN) is expected to report Q3 earnings Wednesday, October 21 after market open, with a conference call scheduled for 5pm ET. GuidanceAnalysts are looking for EPS of $1.27 on revenue of $3.79B. The consensus range is $1.20-$1.34 for EPS, and $3.73B-$3.88B for revenue, according to First Call. In July, the company reported Q2 EPS of $1.12, beating analysts' expectations of $1.02, and revenue of $5.29B, which was slightly lower than consensus estimates of $5.28B. Positive driver's for Amgen's Q3 results could come from international sales and price increases across the drug company's core product portfolio. Mitigating any benefits from price leverage, Amgen is challenged in its anemia franchise with lower revenue expected from Aranesp. The densumab, Proliia project has been delayed as the FDA has requested a "Complete Response Letter" for the biologics license applications for Prolia in the treatment and prevention of postmenopausal osteoporosis. Complete Story »
seekingalpha.com
BioMed News Bytes: AstraZeneca, Delcath, Unilife
Mike Havrilla submits:On 11/19/09, AstraZeneca (NYSE: AZN) announced the submission of a New Drug Application (NDA) to the FDA for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA, pending approval from the FDA. This submission is based on the results of a comprehensive program, including data from PLATO (A Study of Platelet Inhibition and Patient Outcomes), the Phase 3 head-to-head trial comparing ticagrelor plus aspirin with clopidogrel (Plavix) plus aspirin. Ticagrelor is the first reversibly binding oral P2Y12 adenosine diphosphate (ADP) receptor antagonist. The mode of action involves inhibiting the action of platelets in the blood to prevent platelets from sticking together, thereby reducing recurrent thrombotic (blood clot) events. On 5/11/09, AZN announced top line results from the phase III trial, PLATO (A Study of Platelet Inhibition and Patient Outcomes), which demonstrate that BRILINTA (ticagrelor), the investigational oral antiplatelet treatment for acute coronary syndromes (ACS), has achieved a statistically significant primary efficacy endpoint versus Plavix (clopidogrel), in the prevention of cardiovascular (CV) events in patients with ACS. The primary efficacy measure was time to first occurrence of any event from the composite of myocardial infarction, stroke, and CV death. In PLATO, the overall safety profile for BRILINTA was in line with the safety data observed in the Phase 2 studies.Complete Story »
seekingalpha.com
Latest Front in War on Arthritis
Scientists looking for ways to repair damaged cartilage—a leading cause of osteoarthritis—are employing horses to test a new method of tissue regeneration that uses concentrated stem cells.
online.wsj.com